Literature DB >> 7728215

Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients.

L D Altstiel1, B Lawlor, R Mohs, J Schmeidler, A Dalton, P Mehta, K Davis.   

Abstract

A portion of Alzheimer's disease (AD) patients have elevated serum levels of the acute phase reactant alpha 1-antichymotrypsin (A1ACT) compared to age-matched controls. We measured serum levels of A1ACT in AD patients, age-matched controls, Down's syndrome patients, and nondemented first-degree relatives of AD patients. Significantly elevated levels of A1ACT were found in both AD patients and first-degree-relatives. In AD patients, serum A1ACT concentrations decreased with increasing severity of cognitive impairment. These results may suggest that inflammatory phenomena may be an early component of AD pathophysiology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7728215     DOI: 10.1159/000106917

Source DB:  PubMed          Journal:  Dementia        ISSN: 1013-7424


  3 in total

Review 1.  Glucocorticoids in Alzheimer's disease. The story so far.

Authors:  P S Aisen; G M Pasinetti
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

2.  Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study.

Authors:  Matthew Zabel; Matthew Schrag; Claudius Mueller; Weidong Zhou; Andrew Crofton; Floyd Petersen; April Dickson; Wolff M Kirsch
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Novel Exosome Biomarker Candidates for Alzheimer's Disease Unravelled Through Mass Spectrometry Analysis.

Authors:  Tânia Soares Martins; Rui Marçalo; Cristóvão B da Cruz E Silva; Dário Trindade; José Catita; Francisco Amado; Tânia Melo; Ilka Martins Rosa; Jonathan Vogelgsang; Jens Wiltfang; Odete A B da Cruz E Silva; Ana Gabriela Henriques
Journal:  Mol Neurobiol       Date:  2022-02-25       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.